

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
BS	5 1 8 8 9 6 9	02/23/93	Arai et al	436	548	06/15/89

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

Arcl

DATE CONSIDERED

5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
~~1643~~

1644



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>RS</i>	5 8 5 8 3 5 8	01/12/99	June et al	424	130.1	06/03/94

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER


[Signature]

DATE CONSIDERED

5/1/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
~~1643~~ 1644

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
P35	AA	3	8	2	1	0	8	7	6/28/74	Knazek <i>et al.</i>	195	127	5/18/72
	AB	3	8	8	3	3	9	3	5/13/75	Knazek <i>et al.</i>	195	1.8	2/11/74
	AC	3	9	9	7	3	9	6	12/14/76	Delente	195	1.8	7/02/73
	AD	4	0	8	7	3	2	7	5/02/78	Feder <i>et al.</i>	195	1.7	4/12/76
	AE	4	2	0	0	6	8	9	4/29/80	Knazek <i>et al.</i>	435	2	8/29/78
	AF	4	2	0	6	0	1	5	6/03/80	Knazek <i>et al.</i>	435	2	8/29/78
	AG	4	2	2	0	7	2	5	09/02/80	Knazek <i>et al.</i>	435	285	4/03/78
	AH	4	3	0	1	2	4	9	11/17/81	Markus <i>et al.</i>	435	235	7/23/80
	AI	4	3	9	1	9	1	2	7/5/83	Yoshida <i>et al.</i>	435	241	9/18/80
	AJ	4	5	4	6	0	8	3	10/08/85	Meyers <i>et al.</i>	435	240	4/22/83
	AK	4	6	2	9	6	8	6	12/16/86	Gruenberg	435	1	06/14/82
	AL	4	6	9	0	9	1	5	09/01/87	Rosenberg	514	2	08/08/85
	AM	4	7	2	2	9	0	2	02/02/88	Harm <i>et al.</i>	435	284	11/04/85
	AN	4	8	0	4	6	2	8	02/14/89	Cracauer <i>et al.</i>	435	240.242	08/19/87
	AO	4	8	0	8	1	5	1	02/28/89	Dunn, Jr. <i>et al.</i>	604	6	04/27/87
	AP	4	8	4	9	3	2	9	07/18/89	Leung <i>et al.</i>	435	2	04/20/87
	AQ	4	8	6	1	5	8	9	08/29/89	Ju	424	93	03/23/87
	AR	4	8	9	4	3	4	2	01/16/90	Guinn <i>et al.</i>	435	291	09/22/86
	AS	4	9	3	7	0	7	1	06/26/90	Cioco <i>et al.</i>	424	85.2	12/29/87
	AT	4	9	7	1	7	9	5	11/20/90	Longenecker <i>et al.</i>	424	93	07/21/88
	AU	4	9	7	3	5	5	8	11/27/90	Wilson <i>et al.</i>	435	240.242	04/28/88
	AV	4	9	9	9	2	9	8	03/12/91	Wolfe <i>et al.</i>	435	240.242	04/27/88
	AW	5	0	0	2	8	7	9	03/26/91	Bowlin <i>et al.</i>	435	71.1	12/05/89
	AX	5	0	1	5	5	8	5	05/14/91	Robinson	435	240.242	02/23/88
	AY	5	0	4	1	2	8	9	08/20/91	Phillips <i>et al.</i>	424	85.2	11/13/87

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
RB	AZ	5	0	5	7	4	2	3	10/15/91	Hiserodt <i>et al.</i>	435	240.23	12/18/87
	BA	5	0	6	1	6	2	0	10/29/91	Tsukamoto <i>et al.</i>	435	7.21	03/30/90
	BB	5	0	6	4	7	6	4	11/12/91	Besnainon <i>et al.</i>	435	285	12/19/89
	BC	5	1	2	6	1	3	2	06/30/92	Rosenberg	424	93	08/21/89
	BD	5	1	2	6	2	3	8	06/30/92	Gebhard <i>et al.</i>	435	3	02/15/90
	BE	5	1	4	7	2	8	9	09/15/92	Edelson	604	4	03/29/90
	BF	5	1	4	7	7	8	4	09/15/92	Peault	435	7.24	04/12/90
	BG	5	1	6	2	2	2	5	11/10/92	Sager <i>et al.</i>	435	240.243	07/15/91
	BH	5	1	9	2	5	3	7	03/09/93	Osband	424	85.2	08/19/91
	BI	5	2	0	2	2	5	4	04/13/93	Amiot <i>et al.</i>	435	240.242	10/11/90
	BJ	5	2	2	9	1	1	5	07/20/93	Lynch	424	93	07/26/90
	BK	5	2	4	2	6	8	7	09/07/93	Tykocinski <i>et al.</i>	424	93	04/25/91
	BL	5	2	7	7	9	0	7	01/11/94	Loria	424	93	07/24/92
	BM	5	3	1	6	7	6	3	05/31/94	Ochoa <i>et al.</i>	424	85.2	07/10/92
	BN	5	3	2	6	7	6	3	07/05/94	Gluchowski <i>et al.</i>	514	249	01/29/93
	BO	5	3	7	4	5	4	9	12/20/94	Leung	435	240.2	01/31/91
	BP	5	3	9	9	3	4	6	03/21/95	Anderson <i>et al.</i>	424	93.21	03/30/94
	BQ	5	3	9	9	3	4	7	03/21/95	Trentham <i>et al.</i>	424	184.1	09/25/92
	BR	5	4	0	9	8	1	3	04/24/95	Schwartz	435	7.24	09/30/93
	BS	5	4	1	1	7	4	9	05/02/95	Mayo <i>et al.</i>	424	578	12/23/92
	BT	5	4	3	7	9	9	4	08/01/95	Emerson <i>et al.</i>	435	240.2	12/10/93
	BU	5	4	4	3	9	8	3	08/22/95	Ochoa <i>et al.</i>	435	240.2	03/21/88
	BV	5	4	5	9	0	6	9	10/17/95	Palsson <i>et al.</i>	435	289.1	01/06/94
	BW	5	4	6	6	5	7	2	11/14/95	Sasaki <i>et al.</i>	435	2	04/25/94
	BX	5	4	7	0	7	3	0	11/28/95	Greenberg <i>et al.</i>	435	172.3	08/08/94

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
D33	BY	5	4	7	6	9	9	7	12/19/95	Kaneshima <i>et al.</i>	800	2	05/17/94
	BZ	5	4	9	8	5	3	7	03/12/96	Bresler <i>et al.</i>	435	235.1	03/09/94
	CA	5	5	1	2	4	4	4	04/30/96	Patard <i>et al.</i>	435	6	11/30/94
	CB	5	5	9	9	7	0	5	02/04/97	Cameron	435	378	11/16/93
	CC	5	6	0	5	8	2	2	02/25/97	Emerson <i>et al.</i>	435	172.3	12/01/94
	CD	5	6	2	2	8	5	7	04/22/97	Goffe	435	378	08/08/95
	CE	5	6	2	7	0	7	0	05/06/97	Gruenberg	435	786.5	07/26/95
	CF	5	6	3	5	3	8	6	06/03/97	Palsson <i>et al.</i>	435	372	11/02/94
	CG	5	6	3	5	3	8	7	06/03/97	Fei <i>et al.</i>	435	378	04/03/95
	CH	5	6	4	6	0	4	3	07/08/97	Emerson <i>et al.</i>	435	373	03/10/95
	CI	5	6	5	6	4	2	1	08/12/97	Gebhard <i>et al.</i>	435	3	02/12/91
	CJ	5	6	7	6	8	4	9	10/14/97	Sammons <i>et al.</i>	210	806	03/08/95
	CK	5	7	1	8	8	8	3	02/17/98	Harlan <i>et al.</i>	424	9.2	02/17/94
	CL	5	7	2	8	5	8	1	03/17/98	Schwartz <i>et al.</i>	435	385	06/07/95
	CM	5	7	6	3	2	6	1	06/09/98	Gruenberg	435	286.5	12/05/96
	CN	5	7	6	3	2	6	6	06/09/98	Palsson <i>et al.</i>	435	289.1	11/07/94
	CO	5	8	1	1	3	0	1	09/22/98	Cameron	435	372	08/07/96

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
D35	CP	0	4	0	5	9	7	2	1/2/91	EPO	AL	—		
	CQ	9	0	0	5	5	4	1	05/31/90	PCT	—	—		
	CR	9	0	1	5	8	7	7	12/27/90	PCT	—	—		
	CS	9	1	0	4	3	1	7	04/04/91	PCT	—	—		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSUREAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
135	CT	9	1	1	8	9	7	2	12/12/91	PCT	—	—		
	CU	9	3	1	9	7	6	7	10/14/93	PCT	—	—		
	CV	9	4	2	2	4	8	9	10/13/94	PCT	—	—		
	CW	9	4	2	3	7	6	0	10/27/94	PCT	—	—		
	CX	9	4	2	8	9	1	2	12/22/94	PCT	—	—		
	CY	9	4	2	9	4	3	6	12/22/94	PCT	—	—		
	CZ	9	5	2	9	6	7	3	11/09/95	PCT	—	—		
	DA	9	5	3	3	8	2	3	12/14/95	PCT	—	—		
	DB	9	5	3	3	8	2	3	12/14/95	PCT	—	—		
	DC	9	6	3	4	9	5	6	11/07/96	PCT	—	—		
	DD	9	6	3	4	9	7	0	11/7/96	PCT	—	—		
	DE	9	6	4	0	8	6	0	12/19/96	PCT	—	—		
	DF	9	6	4	0	8	7	6	12/19/96	PCT	—	—		
	DG	9	7	0	5	2	3	9	2/13/97	PCT	—	—		
	DH	9	7	3	1	6	4	7	09/04/97	PCT	—	—		
	DI	9	8	2	5	4	5	7	06/18/98	PCT	—	—		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

135	DJ	Alberts, B. <i>et al.</i> , " <u>Molecular Biology of the Cell</u> ", 3rd ed., Garland Publishing, Inc., ppp. 1169 (1994)
	DK	Autran <i>et al.</i> , A ThO/Th2-like function of CD4 ⁺ CD7 ⁺ T helper cells from normal donors and HIV-infected patients, <u>J. Immunol.</u> 154: 1408-1417 (1995)
	DL	Bartholeyns <i>et al.</i> , Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer, <u>Anticancer Research</u> 14: 2673-2676 (1994)

EXAMINER

DATE CONSIDERED

5/1/2005

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

VP35	DM	Benvenuto <i>et al.</i> , Enhanced production of interferon- γ by T lymphocytes cloned from rejected kidney grafts, <u>Transplantation</u> 51: 887-890 (1991)
	DN	Benvenuto <i>et al.</i> , Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis, <u>Clin. Exp. Immunol.</u> 84: 97-102 (1991)
	DO	Bernhard <i>et al.</i> , Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood, <u>Cancer Res.</u> 55: 1099-1104 (1995)
	DP	Boiardi <i>et al.</i> , Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-Lak) in recurrent glioblastoma patients, <u>Cancer Immunol. Immunother.</u> 39: 193-197 (1994)
	DQ	Brod <i>et al.</i> , Restricted T cell expression of IL-2/Ifn- γ mRNA in human inflammatory disease, <u>J. Immunol.</u> 147: 810-815 (1991)
	DR	Cesano <i>et al.</i> , Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach, <u>J. Clin. Invest.</u> 94: 1076-1084 (1994)
	DS	Chen <i>et al.</i> , Donor T cells can be induced to grow and survive long term <i>in vivo</i> without previous host immunosuppression, <u>J. Immunol.</u> 152: 4767-4774 (1994)
	DT	Chen <i>et al.</i> , Regulatory T cell clone induced by oral tolerance: Suppression of autoimmune encephalomyelitis, <u>Science</u> 265: 1237-1240 (1994)
	DU	Cherwinski <i>et al.</i> , Two types of mouse helper T cell clone, <u>J. Exp. Med.</u> 166: 1229-1244 (1987)
	DV	Chick <i>et al.</i> , Beta cell culture on synthetic capillaries: An artificial endocrine pancreas, <u>Science</u> 187: 847-849 (1975)
	DW	Clerici <i>et al.</i> , A T _H 1-T _H 2 switch is a critical step in the etiology of HIV infection, <u>Immunology Today</u> 14.3: 107-111 (1993)
	DX	David <i>et al.</i> , Continuous production of carcinoembryonic antigen in hollow fiber cell culture units: Brief communication, <u>J. Natl. Cancer Inst.</u> 60.2: 303-306 (Feb. 1978)
	DY	Davis, J.E. <i>et al.</i> , "Mass Transfer Between Capillary Blood and Tissues", <u>Chem. Eng. J.</u> , 7:213-225 (1974)
	DZ	de Carli <i>et al.</i> , Cytolytic T cells with Th1- like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy, <u>J. Clin. Endocrinol. Metabol.</u> 77.5: 1120-1124 (1993)
	EA	De Jong <i>et al.</i> , Maturation- and differentiation-dependent responsiveness of human CD4 ⁺ T helper subsets, <u>J. Immunol.</u> 149: 2795-2802 (Oct. 1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

OCT 25 1998

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EB	Del Prete <i>et al.</i> , High potential to tumor necrosis factor x (TNF-x) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: A peculiar feature of destructive thyroid autoimmunity, <u>Autoimmunity</u> 4: 267-276 (1989)
EC	Del Prete <i>et al.</i> , Purified Protein derivative of <i>Mycobacterium tuberculosis</i> and excretory-secretory antigen(s) of <i>Toxocara canis</i> expand <i>in vitro</i> human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production, <u>J. Clin. Invest.</u> 88: 346-350 (July 1991)
ED	Dillman <i>et al.</i> , Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma, <u>Cancer</u> 68: 1-8 (1991)
EE	Dillman <i>et al.</i> , Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A national biotherapy study group trial, <u>J. Clin. Oncology</u> 9.7: 1233-1240 (1991)
EF	Eastcott <i>et al.</i> , Adoptive transfer of cloned T helper cells ameliorates periodontal disease in nude rats, <u>Oral Microbiol. Immunol.</u> 9: 284-289 (1994)
EG	Elson <i>et al.</i> , T cell subpopulation phenotypes in filarial infections: CD27 negativity defines a population greatly enriched for T _H 2 cells, <u>Internat. Immunol.</u> 6: 1003-1009 (1993)
EH	Englemann <i>et al.</i> , Activation of human T lymphocyte subsets: Helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens, <u>J. Immunol.</u> 127: 2124-2129 (1981)
EI	Faradji <i>et al.</i> , Large scale isolation of human blood monocytes by continuous flow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients, <u>J. Immunol. Meth.</u> 174: 297-309 (1994)
EJ	Fiorentino <i>et al.</i> , Two types of mouse T helper cell, <u>J. Exp. Med.</u> 170: 2081-2095 (1989)
EK	Firestein <i>et al.</i> , A new murine CD4 ⁺ T cell subset with an unrestricted cytokine profile, <u>J. Immunol.</u> 143: 518-525 (1989)
EL	Foon <i>et al.</i> , Renal cell carcinoma treated with continuous-infusion interleukin-2 with <i>ex vivo</i> -activated killer cells, <u>J. Immunotherapy</u> 11: 184-190 (1992)
EM	Foulis <i>et al.</i> , Insulinitis in type 1 (insulin-dependent) diabetes mellitus in Man-macrophages, lymphocytes, and interferon- μ containing cells, <u>J. Pathol.</u> 165: 97-103 (1991)
EN	Fowell <i>et al.</i> , Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4 ⁺ T cell subset that inhibits this autoimmune potential, <u>J. Exp. Med.</u> 177: 627-636 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

135	EO	Fowler <i>et al.</i> , Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice, <u>Advances in Bone Marrow Purging and Processing: Fourth International Symposium</u> , 533-540 (1994)
	EP	Freedman <i>et al.</i> , Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial, <u>J. Immunol.</u> 16: 198-210 (1994)
	EQ	Galandrini <i>et al.</i> , Antibodies to CD44 trigger effector functions of human T cell clones, <u>J. Immunol.</u> 150: 4225-4235 (1993)
	ER	Gaudernack <i>et al.</i> , Isolation of pure functionally active CD8 ⁺ T cells positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres, <u>J. Immun. Meth.</u> 90: 179-187 (1986)
	ES	Goedegbuure <i>et al.</i> , Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study, <u>J. Clin. Oncol.</u> 13: 1939-1949 (1995)
	ET	Gold <i>et al.</i> , Adoptive Tumor immunotherapy using human CD4 ⁺ T-cells, <u>Br. J. Cancer</u> 67: 865 (1993)
	EU	Gold <i>et al.</i> , Autolymphocyte therapy, <u>J. Surgical Res.</u> 59: 270-286 (1995)
	EV	Grabbe <i>et al.</i> , Dendritic cells as initiators of tumor immune responses: A Possible strategy for tumor immunotherapy, <u>Immunology Today</u> 16: 117-121 (1995)
	EW	Graham <i>et al.</i> , The use of <i>ex vivo</i> -activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study, <u>Seminars in Urology</u> 11: 27-34 (1993)
	EX	Grau <i>et al.</i> , Implications of cytokines in immunopathology: Experimental and clinical data, <u>Eur. Cytokine Net.</u> 1: 203-210 (1990)
	EY	Grimm <i>et al.</i> , Lymphyokine-activated killer cell phenomenon, <u>J. Exp. Med.</u> 155: 1823-1841 (1982)
	EZ	Gullino <i>et al.</i> , Tissue culture on artificial capillaries, <u>Meth. Enzymol.</u> 58: 178-184 (1979)
	FA	Hager <i>et al.</i> , Tumor-associated antigens produced by mouse mammary tumor cells in artificial capillary culture, <u>J. Natl. Cancer Inst.</u> 69: 1359-1365 (1982)
	FB	Hammel <i>et al.</i> , Effect of interleukin-1 α on the <i>in vitro</i> activation of tumor-draining lymph node cells for adoptive immunotherapy, <u>J. Immunotherapy</u> 16: 1-12 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

OCT 25 1998

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


✓ 35	FC	Hansen <i>et al.</i> , Monoclonal antibodies identifying a novel T-cell antigen and Ia antigen of human lymphocytes, <u>Immunogenetics</u> 10: 247-260 (1980)
	FD	Hara <i>et al.</i> , Human T cell activation, <u>J. Exp. Med.</u> 161: 1513-1524 (1985)
	FE	Henschler <i>et al.</i> , Maintenance of transplantation potential in <i>ex vivo</i> expanded CD34 ⁺ - selected human peripheral blood progenitor cells, <u>Blood</u> 84: 2898-2903 (1994)
	FF	Herberman <i>et al.</i> , Adoptive therapy with purified CD8 cells in HIV infection, <u>AIDS/Cancer Therapies</u> , 35-44.
	FG	Ho <i>et al.</i> , A phase 1 study of adoptive transfer of autologous CD8 ⁺ lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS, <u>Blood</u> 81: 2093-2101 (1993)
	FH	Hsieh <i>et al.</i> , Differential regulation of T helper phenotype development by interleukins 4 and 10 in an $\alpha\beta$ T-cell-receptor transgenic system, <u>Proc. Natl. Acad. Sci. USA</u> 89: 6065-6089 (1992).
	FI	Huet <i>et al.</i> , T cell activation via CD2 [T, gp50]: The role of accessory cells in activating resting T cells via CD2, <u>J. Immunol.</u> 137: 1420-1428 (1986)
	FJ	Igletseme <i>et al.</i> , Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, TH ₁ Lymphocyte clone, <u>Regional Immunology</u> 5: 317-324 (1993)
	FK	Jensen <i>et al.</i> , Production of anchorage-dependent cells-problems and their possible solutions, <u>Biotechnol. Bioeng.</u> 23: 2703-2716 (1981)
	FL	Klimas <i>et al.</i> , Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion, <u>AIDS</u> 8: 1073-1081 (1994)
	FM	Knazek <i>et al.</i> , Cell culture on artificial capillaries: An approach to tissue growth <i>in vitro</i> , <u>Science</u> 173: 65-67 (1972)
	FN	Knazek <i>et al.</i> , Hormone production by cells grown in vitro on artificial capillaries, <u>Exp. Cell Res.</u> 84: 251-254 (1974)
	FO	Knazek <i>et al.</i> , Brief communication: Formation of solid human mammary carcinoma <i>in vitro</i> , <u>J. Natl. Cancer Inst.</u> 58: 419-422 (1977)
	FP	Koretz <i>et al.</i> , Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer, <u>Arch. Surg.</u> 126: 898-903 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


1235	FQ	Lane <i>et al.</i> , Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation, <u>Blood</u> 85: 275-282 (1995)
	FR	Lea <i>et al.</i> , Characterization of human mononuclear cells after positive selection with immunomagnetic particles, <u>Scand. J. Immunol.</u> 23: 509-519 (1986)
	FS	Lea <i>et al.</i> , Magnetic Monosized polymer particles for fast and specific fractionation of human mononuclear cells, <u>Scan. J. Immunol.</u> 22: 207-216 (1985)
	FT	Ledbetter <i>et al.</i> , Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells, <u>J. Immunol.</u> 135: 2331-2336 (1985)
	FU	Ledbetter <i>et al.</i> , Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression, <u>J. Immunol.</u> 135: 1819-1825 (1985)
	FV	Ledbetter <i>et al.</i> , Signal transduction through CD4 receptors: Stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor, <u>Eur. J. Immunol.</u> 18: 525-532 (1988)
	FW	Liblau <i>et al.</i> , Th1 and Th2 CD4 ⁺ T Cells in the pathogenesis of organ-specific autoimmune diseases, <u>Immunology Today</u> 16: 34-38 (1995)
	FX	Lindqvist <i>et al.</i> , Enhanced IL-4-mediated D10.G4.1 Proliferation with suboptimal concentrations of anti-IL-4 receptor Monoclonal antibodies, <u>J. Immunol.</u> 150: 394-398 (1993)
	FY	Lum <i>et al.</i> , In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen, <u>Cell. Immunol.</u> 72: 122-129 (1982)
	FZ	Luyten <i>et al.</i> , Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation, <u>J. Biol. Chem.</u> 264(23):13377-13380 (1989)
	GA	Lynch <i>et al.</i> , Interleukin 7 promotes long-term <i>in vitro</i> growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy <i>in vivo</i> , <u>J. Exp. Med.</u> 179: 31-42 (1994)
	GB	Manetti <i>et al.</i> , CD30 expression by CD8 ⁺ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8 ⁺ CD30 ⁺ T cell clones in human immunodeficiency virus infection, <u>J. Exp. Med.</u> 180: 2407-2411 (1994)
	GC	Manger <i>et al.</i> , T cell activation: Differences in the signals required for IL 2 Production by nonactivated and activated T cells, <u>J. Immunol.</u> 135: 3669-3673 (1985)
	GD	Marcus <i>et al.</i> , The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced <i>in vivo</i> antitumor activity, <u>J. Immunotherapy</u> 15: 105-112 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


P35	GE	Mastsumura <i>et al.</i> , Characteristics and <i>in vivo</i> homing of long-term T-cell Lines and clones derived from tumor-draining lymph nodes, <u>Cancer Res.</u> 54: 2744-2750 (1994)
	GF	Miller <i>et al.</i> , Large scale <i>ex vivo</i> expansion and activation of human natural killer cells for autologous therapy, <u>Bone Marrow Transplantation</u> 14: 555-562 (1994)
	GG	Mosmann <i>et al.</i> , TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties, <u>Ann. Rev. Immunology</u> 7: 145-173 (1989)
	GH	Mosmann <i>et al.</i> , The expanding universe of T-cell subset: Th1, Th2 and more, <u>Immunology Today</u> (March 1996).
	GI	Mosmann <i>et al.</i> , Two types of murine helper T cell clone, <u>J. Immunol.</u> 136: 2348-2357 (1986)
	GJ	Mulder <i>et al.</i> , Culture of tumor-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumor cells does not affect tumor-specificity, <u>Cancer Immunol. Immunother.</u> 41: 293-301 (1995)
	GK	Nagler <i>et al.</i> , Red blood cell depletion and enrichment of CD34 ⁺ Hematopoietic progenitor cells from human umbilical cord blood using soybean agglutinin and CD34 immunoselection, <u>Exp. Hematol.</u> 22: 1134-1140 (1994)
	GL	Nakajima <i>et al.</i> , Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression, <u>Proc. Natl. Acad. Sci. USA</u> 91: 7889-7893 (1994)
	GM	Niessner <i>et al.</i> , Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR), <u>Clin. Exp. Immunol.</u> 101: 428-435 (1995)
	GN	O'Garra <i>et al.</i> , Role of cytokines in determining T-lymphocyte function, <u>Immunology</u> 6: 458-466 (1994)
	GO	Ohno <i>et al.</i> , Lectin-activated Killer cells rapidly induced by pokeweed mitogen conjugated beads and their <i>in vivo</i> antitumor effects, <u>Int. J. Immunopharmacol.</u> 16: 761-768 (1994)
	GP	Okamoto <i>et al.</i> , The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells, <u>Cancer Immunol. Immunother.</u> 40: 173-181 (1995)
	GQ	Okarma <i>et al.</i> , The AIS collector: A new technology for stem cell purification, <u>Advances in Bone Marrow Purging and Processing</u> 487-504 (1992)
	GR	Oxholm <i>et al.</i> , Cytokine expression in labial salivary glands from patients with primary Sjogrens syndrome, <u>Autoimmunity</u> 12: 185-191 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

P35	GS	Palliard <i>et al.</i> , Simultaneous production of IL-2, IL-4, and IFN- μ by activated human CD4 ⁺ and CD8 ⁺ T cell clones, <u>J. Immunol.</u> 141: 849-855 (1988)
	GT	Pierrès <i>et al.</i> , Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation, <u>Eur. J. Immunol.</u> 18: 685-690 (1988)
	GU	Polanski <i>et al.</i> , Differentiation of Th2 cells from precursors in ra peripheral blood, (submitted 1996)
	GV	Powrie <i>et al.</i> , Regulatory interactions between CD45RB ^{High} and CD45RB ^{Low} CD4 ⁺ T cells are important for the balance between protective and pathogenic cell-mediated immunity, <u>J. Exp. Med.</u> 179: 589-600 (1994)
	GW	Puchetti <i>et al.</i> , A T _H 1-T _H 2-like switch in candidiasis: New perspectives for therapy, <u>Trends Microbiol.</u> 3(6): 237-240 (1995)
	GX	Quayle <i>et al.</i> , Theumatoid inflammatory T-cell clones express mostly Th-1 but also Th2 and mixed (Th0-like) cytokine patterns, <u>Scand. J. Immunol.</u> 38: 75-82 (1993)
	GY	Reinherz <i>et al.</i> , Separation of functional subsets of human T cells by a monoclonal antibody, <u>Proc. Natl. Acad. Sci. USA</u> 76: 4061-4065 (1979)
	GZ	Riddell <i>et al.</i> , Principles for adoptive T cell therapy of human viral diseases, <u>Ann. Rev. Immunology</u> 13: 545-586 (1995)
	HA	Riddell <i>et al.</i> , Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones, <u>Science</u> 257: 238-241 (1992)
	HB	Riddell <i>et al.</i> , CD8 ⁺ cytotoxic T cell therapy of cytomegalovirus and HIV infection, <u>Immunology</u> 5: 484-491 (1993)
	HC	Romagnani <i>et al.</i> , Regulation of the development of type 2 T-helper cells in allergy, <u>Immunology</u> 6: 838-846 (1994)
	HD	Romagnani <i>et al.</i> , HIV can induce a T _H 1 to T _H 0 shift, and preferentially replicates in CD4 ⁺ T-cell clones producing T _H 2-type cytokines, <u>60th Forum in Immunology</u> , 611-617 (1994)
	HE	Romani <i>et al.</i> , Proliferating dendritic cell progenitors in human blood, <u>J. Exp. Med.</u> 180: 83-93, (1994).
	HF	Romani <i>et al.</i> , Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance, <u>Infection and Immunity</u> 59: 4647-4654 (1991)
	HG	Rosenberg <i>et al.</i> , Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, <u>N. Engl. J. Med.</u> 313: 1485-1492 (1985)

EXAMINER

DATE CONSIDERED

5/1/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

OCT 26 1998

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

P35	HH	Rosenberg <i>et al.</i> , A progress on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, <u>N. Engl. J. Med.</u> 316: 889-897 (1987)
	HI	Rosenberg <i>et al.</i> , Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, <u>N. Engl. J. Med.</u> 319: 1676-1680 (1988)
	HJ	Rutzky <i>et al.</i> , Human colon adenocarcinoma cells. III. <i>In vitro</i> organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture, <u>J. Natl. Cancer Inst.</u> 63: 85-93 (1979)
	HK	Sacchi <i>et al.</i> , Induction of tumor regression in experimental model of human head and neck cancer by human A-Lak cells and IL-2, <u>Int. J. Cancer</u> , 47: 784-791 (1991)
	HL	Salgaller <i>et al.</i> , Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides, <u>Cancer Res.</u> 55: 4972-4979 (1995)
	HM	Saoudi <i>et al.</i> , TH2 activated cells prevent experiential autoimmune unweoretinitis, a TH1-dependent autoimmune disease, <u>Eur. J. Immunol.</u> 23: 3096-3103 (1993)
	HN	Scott <i>et al.</i> , The role of T-cell subsets and cytokines in the regulation of infection, <u>Immunology Today</u> , 12: 346-348, (1991).
	HO	Scott, P. <i>et al.</i> , "Role of Cytokines and CD4+ T-Cell Subsets in the Regulation of Parasite Immunity and Disease", <u>Immunol. Rev.</u> , 112:161-182 (1989)
	HP	Seder <i>et al.</i> , Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon μ production and diminishes interleukin 4 inhibition of such priming, <u>Proc. Natl. Acad. Sci. USA</u> 90: 10188-10192 (1993)
	HQ	Sedlmayr <i>et al.</i> , Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells, <u>J. Immunotherapy</u> 10: 336-346 (1991)
	HR	Shanafelt <i>et al.</i> , Costimulatory signals can selectively modulate cytokine production by subsets of CD4+ T cells, <u>J. Immunol.</u> 154: 1684-1690 (1995).
	HS	Sher <i>et al.</i> , Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection, <u>Immunological Rev.</u> 127: 183-204 (1992).
	HT	Shimizu <i>et al.</i> , Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin, <u>J. Immunol.</u> 145: 59-67 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

OCT 26 1998

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

VB5	HU	Simon <i>et al.</i> , Divergent T-cell cytokine patterns in inflammatory arthritis, <u>Proc. Natl. Acad. Sci. USA</u> 91: 8562-8566 (1994)
	HV	Spertini <i>et al.</i> , Signals delivered via MHC class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells, <u>J. Immunol.</u> 149: 65-70 (1992)
	HW	Springer <i>et al.</i> , Adhesion receptors of the immune system, <u>Nature</u> 346: 425-434 (1990)
	HX	Sugie <i>et al.</i> , Stimulation of NK-like YT cells via leukocyte function-associated antigen (LFA)-1, <u>J. Immunol.</u> 154: 1691-1698 (1995)
	HY	Swabb <i>et al.</i> , Diffusion and convection in normal and neoplastic tissues, <u>Cancer Res.</u> 34: 2814-2814 (1974)
	HZ	Sznol <i>et al.</i> , Adoptive immunotherapy, <u>Cancer Chemotherapy and Biological Responses Modifiers Annual</u> 14: 227-248 (1993)
	IA	Takahashi <i>et al.</i> , Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion, <u>Jpn. J. Cancer Res.</u> 86: 861-866 (1995)
	IB	Tamura <i>et al.</i> , T cell activation through TCR-/CD3 complex IL-2 production of T cell clones stimulated with anti-CD3 without cross-linkage, <u>J. Immunol.</u> 148: 2370-2377 (1992)
	IC	Tax <i>et al.</i> , Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells, <u>Nature</u> 304: 445-447 (1983)
	ID	Thompson <i>et al.</i> , Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma, <u>J. Clin. Oncol.</u> 10: 960-968 (1992)
	IE	Thygesen <i>et al.</i> , Immunity to experimental <i>Salmonella typhimurium</i> infections in rats, <u>APMIS</u> 102: 489-494 (1994)
	IF	Torpey, Effects of adoptive immunotherapy with autologous VS8+ T lymphocytes on immunologic parameters: Lymphocyte subsets and cytotoxic, <u>Clinical Immunol. Immunopathol.</u> 68: 263-272 (1993)
	IG	Toso, J.F. <i>et al.</i> , "MAGE-1-Specific Precursor Cytotoxic T-Lymphocytes Present among Tumor-Infiltrating Lymphocytes from a Patient with Breast Cancer: Characterization and Antigen-Specific Activation", <u>Cancer Res.</u> , 56:16-20 (1996)
	IH	Turner <i>et al.</i> , Human T cells from autoimmune and normal individuals can produce tumor necrosis factor, <u>Eur. J. Immunol.</u> 17: 1807-1814 (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

OCT 26 1998

ATTY. DOCKET NO.
24731-500ESERIAL NO.
09/127,138LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERGFILING DATE
7/31/98GROUP
1643

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BS	II	Tze <i>et al.</i> , Long-term survival of adult rat islets of Langerhans in artificial capillary culture units, <u>Diabetes</u> , 26: 185-191 (1977)
	IJ	Urban <i>et al.</i> , The importance of Th2 cytokines in protective immunity to nematodes, <u>Immunological Reviews</u> , 127: 205-220 (1992)
	IK	Utsugi <i>et al.</i> , Prevention of recurrent diabetes in syngeneic islet-transplanted NOD Mice by transfusion of autoreactive T lymphocytes, <u>Transplantation</u> 57: 1799-1804 (1994)
	IL	Van Lier <i>et al.</i> , Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen, <u>J. Immunol.</u> 139: 1589-1596 (1987)
	IM	Van Lunzen <i>et al.</i> , Investigations on autologous T-cells for adoptive immunotherapy of AIDS, <u>Cell Activation and Apoptosis in HIV Infection</u> , 6: 57-70 (1995)
	IN	Vandenberghe <i>et al.</i> , Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: Evidence for signal transduction through CD5, <u>Eur. J. Immunol.</u> 21: 251-259 (1991)
	IO	Whiteside <i>et al.</i> , Generation and characterization of <i>ex vivo</i> propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus, <u>Blood</u> , 81: 2085-2092 (1993)
	IP	Wolf <i>et al.</i> , Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries, <u>Tran. Amer. Soc. Artif. Int. Organs.</u> 21: 16-27 (1975)
	IQ	Yamamura <i>et al.</i> , Defining protective responses to pathogens: Cytokine profiles in leprosy lesions, <u>Science</u> 254: 277-279 (1991)
	IR	Yang <i>et al.</i> , <i>In vitro</i> priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation, <u>J. Immunol.</u> 155: 3897-3903 (1995)
	IS	Yannelli <i>et al.</i> , The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer, <u>Journal of Immunological Methods</u> 139: 1-16 (1991)
	IT	Zhang <i>et al.</i> , T-cell cytokine responses in human infection with <i>Mycobacterium tuberculosis</i> , <u>Infectious Immunology</u> : 3231-3234 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.